Cargando…

Macular Ganglion Cell Complex and Peripapillary Retinal Nerve Fiber Layer Thinning in Patients with Type-1 Gaucher Disease

Type-1 Gaucher disease (GD1) is considered to be non- neuronopathic however recent evidence of neurological involvement continues to accumulate. There is limited evidence of retinal abnormalities in GD1. The purpose of this study was to evaluate the retinal findings of patients with GD1. Thirty GD1...

Descripción completa

Detalles Bibliográficos
Autores principales:	Weill, Yishay, Zimran, Ari, Zadok, David, Wasser, Lauren M., Revel-Vilk, Shoshana, Hanhart, Joel, Dinur, Tama, Arkadir, David, Becker-Cohen, Michal
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7582605/ https://www.ncbi.nlm.nih.gov/pubmed/32987733 http://dx.doi.org/10.3390/ijms21197027

Ejemplares similares

Real-Life Experience with Oral Eliglustat in Patients with Gaucher Disease Previously Treated with Enzyme Replacement Therapy
por: Istaiti, Majdolen, et al.
Publicado: (2022)

Long Term Follow-Up of 103 Untreated Adult Patients with Type 1 Gaucher Disease
por: Dinur, Tama, et al.
Publicado: (2019)

Patient reported outcome measures in a large cohort of patients with type 1 Gaucher disease
por: Dinur, Tama, et al.
Publicado: (2020)

High-Dose Ambroxol Therapy in Type 1 Gaucher Disease Focusing on Patients with Poor Response to Enzyme Replacement Therapy or Substrate Reduction Therapy
por: Istaiti, Majdolen, et al.
Publicado: (2023)

A Comprehensive Assessment of Qualitative and Quantitative Prodromal Parkinsonian Features in Carriers of Gaucher Disease—Identifying Those at the Greatest Risk
por: Becker-Cohen, Michal, et al.
Publicado: (2022)

Impact of Long-Term Enzyme Replacement Therapy on Glucosylsphingosine (Lyso-Gb1) Values in Patients with Type 1 Gaucher Disease: Statistical Models for Comparing Three Enzymatic Formulations
por: Dinur, Tama, et al.
Publicado: (2021)

Contribution of Glucosylsphingosine (Lyso-Gb1) to Treatment Decisions in Patients with Gaucher Disease
por: Dinur, Tama, et al.
Publicado: (2023)

Glucosylsphingosine (lyso-Gb1) as a Biomarker for Monitoring Treated and Untreated Children with Gaucher Disease
por: Hurvitz, Noa, et al.
Publicado: (2019)

Gaucher Disease Diagnosis Using Lyso-Gb1 on Dry Blood Spot Samples: Time to Change the Paradigm?
por: Dinur, Tama, et al.
Publicado: (2022)

Value of Glucosylsphingosine (Lyso-Gb1) as a Biomarker in Gaucher Disease: A Systematic Literature Review
por: Revel-Vilk, Shoshana, et al.
Publicado: (2020)

Improvement in bone marrow infiltration in patients with type I Gaucher disease treated with taliglucerase alfa
por: Zimran, Ari, et al.
Publicado: (2018)

The definition of neuronopathic Gaucher disease
por: Schiffmann, Raphael, et al.
Publicado: (2020)

Simultaneous Bilateral Femoral Osteonecrosis in Gaucher Disease
por: Cohen, Daniel, et al.
Publicado: (2023)

Brain-Derived Neurotrophic Factor (BDNF) Is Associated with Platelet Activity and Bleeding Tendency in Patients with Gaucher Disease
por: Azoulay, David, et al.
Publicado: (2022)

The Bone Biomarker of Quantitative Chemical Shift Imaging in Patients with Type 1 Gaucher Disease Receiving Low-Dose Long-Term Enzyme Replacement Therapy
por: Zimran, Ari, et al.
Publicado: (2023)

Anesthetic Approaches and Perioperative Complications of Total Hip Arthroplasty in Gaucher Disease: A Control-Matched Retrospective-Cohort Study
por: Grass, Ariel, et al.
Publicado: (2023)

Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS)
por: Hughes, Derralynn A., et al.
Publicado: (2022)

Effects of delay in anti-vascular endothelial growth factor intravitreal injections for neovascular age-related macular degeneration
por: Hanhart, Joel, et al.
Publicado: (2022)

Reply to Mistry et al. The Two Substrate Reduction Therapies for Type 1 Gaucher Disease Are Not Equivalent. Comment on “Hughes et al. Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS). J. Clin. Med. 2022, 11, 5158”
por: Hughes, Derralynn A., et al.
Publicado: (2023)

Real-World Experiences with Taliglucerase Alfa Home Infusions for Patients with Gaucher Disease: A Global Cohort Study
por: Revel-Vilk, Shoshana, et al.
Publicado: (2023)

A Deep-Learning Approach to Spleen Volume Estimation in Patients with Gaucher Disease
por: Azuri, Ido, et al.
Publicado: (2023)

Cancer risk and gammopathies in 2123 adults with Gaucher disease type 1 in the International Gaucher Group Gaucher Registry
por: Rosenbloom, Barry E., et al.
Publicado: (2022)

Insights into the Value of Lyso-Gb1 as a Predictive Biomarker in Treatment-Naïve Patients with Gaucher Disease Type 1 in the LYSO-PROOF Study
por: Curado, Filipa, et al.
Publicado: (2023)

A Rare Case of Acute Bilateral Endothelial Decompensation after Prophylactic Nd:YAG Laser Iridotomy Requiring Endothelial Keratoplasty
por: Weill, Yishay, et al.
Publicado: (2020)

P1633: LOW SERUM BDNF LEVELS ARE ASSOCIATED WITH LOWER PLATELETS’ CD62P REACTIVITY AND INCREASED BLEEDING TENDENCY IN PATIENTS WITH GAUCHER DISEASE
por: Azoulay, D., et al.
Publicado: (2022)

The Impact of COVID-19 on Intravitreal Injection Compliance
por: Wasser, Lauren M., et al.
Publicado: (2020)

Response of ophthalmologists in Israel to the novel coronavirus (2019-nCoV) outbreak
por: Wasser, Lauren M., et al.
Publicado: (2020)

Hepatocellular carcinoma in Gaucher disease: an international case series
por: Regenboog, Martine, et al.
Publicado: (2018)

A global neuronopathic gaucher disease registry (GARDIAN): a patient-led initiative
por: Collin-Histed, Tanya, et al.
Publicado: (2023)

Review of the safety and efficacy of imiglucerase treatment of Gaucher disease
por: Elstein, Deborah, et al.
Publicado: (2009)

Fertility preservation in young cancer patients
por: Revel, Ariel, et al.
Publicado: (2010)

Dental profile of patients with Gaucher disease
por: Fischman, Stuart L, et al.
Publicado: (2003)

Patient blood management programs: how to spread the word?
por: Revel-Vilk, Shoshana, et al.
Publicado: (2018)

Characteristics of 26 patients with type 3 Gaucher disease: A descriptive analysis from the Gaucher Outcome Survey
por: Schwartz, Ida Vanessa D., et al.
Publicado: (2017)

Occurrence of Amyotrophic Lateral Sclerosis in Type 1 Gaucher Disease
por: Oliveira, Lais M., et al.
Publicado: (2021)

Patient centered guidelines for the laboratory diagnosis of Gaucher disease type 1
por: Dardis, A., et al.
Publicado: (2022)

Telemedicine comes of age during coronavirus disease 2019 (COVID-19): An international survey of oculoplastic surgeons
por: Assayag, Elishai, et al.
Publicado: (2020)

An unusual case of globe-sparing penetrating orbital injury by a nail
por: Weill, Yishay, et al.
Publicado: (2018)

Choroidal Nevus-Associated Neovascular Membrane Demonstrated by OCT Angiography
por: Hanhart, Joel, et al.
Publicado: (2017)

Taliglucerase alfa: safety and efficacy across 6 clinical studies in adults and children with Gaucher disease
por: Zimran, Ari, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_i7f0pghl6klddhhs1cchul0onq